Product Description
Immoon Therapeutics is a pre-clinical stage biotech company developing first-in-class small molecule inhibitors to treat autoimmune diseases and B-cell lymphomas. We are looking into the "root cause" of a problem and addressing the formation of pathologic antibodies in autoimmune diseases. (Sourced from: https://www.linkedin.com/company/immoon-therapeutics/about/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immoon Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified|Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|